The Spanish office will be lead by Pablo Rebollo. Pablo has over 20 years of experience in Spanish market access consulting and is specialized in HEOR and PRO measures. With Pablo, we aim to target markets with over 400 million people. If you have any questions on our Spanish capabilities, please contact Pablo Rebollo by
We are happy to share with you our latest publication on time-to-event outcomes in patients with nonmetastatic castration-resistant prostate cancer (NM-CRPC). For these patients, currently, no effective treatments resulting in longer survival compared with watchful waiting are available. On average, without additional treatment, half of these patients survive around 45 months after NM-CRPC diagnosis. Interested?